Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2(+) breast cancer patients

Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Scaltriti, Maurizio, Eichhorn, Pieter J., Cortés, Javier, Prudkin, Ludmila, Aura, Claudia, Jiménez, José, Chandarlapaty, Sarat, Serra, Violeta, Prat, Aleix, Ibrahim, Yasir H., Guzmán, Marta, Gili, Magui, Rodríguez, Olga, Rodríguez, Sonia, Pérez, José, Green, Simon R., Mai, Sabine, Rosen, Neal, Hudis, Clifford, Baselga, José
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2011
Teme:
Biological Sciences
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048107/
https://ncbi.nlm.nih.gov/pubmed/21321214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1014835108
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items